

| | | |
|---|---|---|
| 1 | Table of contents | |
| 2 | Supplementary Table 1: in-house generated antibodies | 2 |
| 3 | Supplementary Fig. 1. Cleaved GPV preferentially localises to fibrin adjacent to thrombus. | 3 |
| 4 | Supplementary Fig. 2. Exemplified gating strategy based on FSC/SSC characteristics. | 4 |
| 5 | References..... | 5 |
| 6 | | |
| 7 | | |

1 **Supplementary Table 1: in-house generated antibodies**


| Antigen | Clone | Source | Reference |
|---------------------------|--------------|--------------------|------------------|
| Mouse P-selectin | WUG1.9 | In-house generated | ¹ |
| Mouse GPIIb/IIIa | JON/A-PE | In-house generated | ² |
| Mouse GPIX | p0p6 | In-house generated | ³ |
| Mouse GPV | DOM/B | In-house generated | this study |
| Mouse GPV | DOM/C | In-house generated | this study |
| Mouse GPV | DOM3 | In-house generated | ⁴ |
| Human GPV | LUM/B | In-house generated | this study |
| Human GPV | LUM1 | In-house generated | this study |
| Human GPV | LUM2 | In-house generated | this study |
| Human GPV | LUM3 | In-house generated | this study |
| Human GPV | LUM4 | In-house generated | this study |
| Human GPV | LUM5 | In-house generated | this study |
| Mouse α 2 integrin | LEN/B | In-house generated | ⁵ |
| Mouse/human GPVI | JAQ1 | In-house generated | ⁶ |
| Mouse GPIIb/IIIa | JON1 | In-house generated | ⁴ |
| Mouse GPIIIa | EDL1 | In-house generated | ⁴ |
| Mouse Integrin α 2 | LEN1 | In-house generated | ⁷ |
| Mouse Integrin α 5 | BAR1 | In-house generated | ⁸ |
| Mouse CD9 | ULF1 | In-house generated | ⁹ |
| Mouse CD84 | JER-1 | In-house generated | ¹⁰ |

| | | | |
|--------------------------|-------|--------------------|----|
| Mouse GPIb α | p0p/B | In-house generated | 11 |
| Mouse GPIb α | p0p4 | In-house generated | 12 |
| Mouse/human GPIb β | p0p1 | In-house generated | 13 |

2

3 The novel antibodies were generated by hybridoma technology following immunisation of *Gp5^{-/-}*
 4 mice or Wistar rats with recombinant hGPV protein or GPV immunoprecipitated from mouse or
 5 human platelet lysates.

6




7

8 **Supplementary Fig. 1. Cleaved GPV preferentially localises to fibrin adjacent to thrombus.**

9 **(a)** Image analysis pipeline to quantify GPV intensities (stained with AF546-labeled DOM/C)
 10 inside fibrin fibres (Fibrin(ogen) AF488) and outside the thrombus (platelets labelled with anti-
 11 GPIX derivative AF405). **(b)** First, GPV signal was analysed inside and outside the
 12 thrombus/fibrin. **(c)** GPV intensities was calculated inside fibrin but outside GPIX-positive area.

13

14



15

16 **Supplementary Fig. 2. Exemplified gating strategy based on FSC/SSC characteristics.**

17

18

19

References

- 20 1 Schulte, V. *et al.* Targeting of the collagen-binding site on glycoprotein VI is not essential
21 for in vivo depletion of the receptor. *Blood* **101**, 3948-3952, doi:10.1182/blood-2002-10-
22 3242 (2003).
- 23 2 Bergmeier, W. *et al.* Flow cytometric detection of activated mouse integrin α IIb β 3
24 with a novel monoclonal antibody. *Cytometry* **48**, 80-86, doi:10.1002/cyto.10114 (2002).
- 25 3 Stegner, D. *et al.* Thrombopoiesis is spatially regulated by the bone marrow vasculature.
26 *Nature communications* **8**, 127, doi:10.1038/s41467-017-00201-7 (2017).
- 27 4 Nieswandt, B., Bergmeier, W., Rackebrandt, K., Gessner, J. E. & Zirngibl, H.
28 Identification of critical antigen-specific mechanisms in the development of immune
29 thrombocytopenic purpura in mice. *Blood* **96**, 2520-2527 (2000).
- 30 5 Shida, Y. *et al.* Analysis of the role of von Willebrand factor, platelet glycoprotein VI-,
31 and α 2 β 1-mediated collagen binding in thrombus formation. *Blood* **124**, 1799-1807,
32 doi:10.1182/blood-2013-09-521484 (2014).
- 33 6 Nieswandt, B. *et al.* Long-term antithrombotic protection by in vivo depletion of platelet
34 glycoprotein VI in mice. *J. Exp. Med.* **193**, 459-469, doi:10.1084/jem.193.4.459 (2001).
- 35 7 Nieswandt, B. *et al.* Expression and function of the mouse collagen receptor glycoprotein
36 VI is strictly dependent on its association with the FcR γ chain. *J. Biol. Chem.* **275**,
37 23998-24002, doi:10.1074/jbc.M003803200 (2000).
- 38 8 Gruner, S. *et al.* Multiple integrin-ligand interactions synergize in shear-resistant platelet
39 adhesion at sites of arterial injury in vivo. *Blood* **102**, 4021-4027, doi:10.1182/blood-2003-
40 05-1391 (2003).
- 41 9 Nieswandt, B. *et al.* Glycoprotein VI but not α 2 β 1 integrin is essential for platelet
42 interaction with collagen. *The EMBO Journal* **20**, 2120-2130,
43 doi:10.1093/emboj/20.9.2120 (2001).
- 44 10 Hofmann, S., VÖGtle, T., Bender, M., Rose-John, S. & Nieswandt, B. The SLAM family
45 member CD84 is regulated by ADAM10 and calpain in platelets. *J. Thromb. Haemost.* **10**,
46 2581-2592, doi:10.1111/jth.12013 (2012).
- 47 11 Massberg, S. *et al.* A crucial role of glycoprotein VI for platelet recruitment to the injured
48 arterial wall in vivo. *J. Exp. Med.* **197**, 41-49 (2003).
- 49 12 Bergmeier, W., Rackebrandt, K., Schroder, W., Zirngibl, H. & Nieswandt, B. Structural
50 and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with
51 novel monoclonal antibodies. *Blood* **95**, 886-893 (2000).
- 52 13 Nieswandt, B. *et al.* Acute systemic reaction and lung alterations induced by an antiplatelet
53 integrin GPIIb/IIIa antibody in mice. *Blood* **94**, 684-693 (1999).

54